158 related articles for article (PubMed ID: 38478074)
1. Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Ogawa A; Kawamoto H; Hara J; Kikuta A; Ogawa C; Hiraga H; Yoshimura K; Miyairi K; Omori R; Ro T; Kamei Y; Kimura T
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38478074
[TBL] [Abstract][Full Text] [Related]
2. Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy.
Fukaya Y; Kimura T; Hamada Y; Yoshimura K; Hiraga H; Yuza Y; Ogawa A; Hara J; Koh K; Kikuta A; Koga Y; Kawamoto H
Front Oncol; 2023; 13():1003633. PubMed ID: 36793598
[TBL] [Abstract][Full Text] [Related]
3. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
4. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
5. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
6. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
Schaff LR; Lobbous M; Carlow D; Schofield R; Gavrilovic IT; Miller AM; Stone JB; Piotrowski AF; Sener U; Skakodub A; Acosta EP; Ryan KJ; Mellinghoff IK; DeAngelis LM; Nabors LB; Grommes C
BMC Cancer; 2022 Jan; 22(1):60. PubMed ID: 35027038
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.
Krüger C; Engel N; Reinert J; Alsdorf W; Fiedler W; Dierlamm J; Bokemeyer C; Langebrake C
Pharmacotherapy; 2020 May; 40(5):479-483. PubMed ID: 32239519
[TBL] [Abstract][Full Text] [Related]
8. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.
Rosales A; Madrid A; Muñoz M; Dapena JL; Ariceta G
Front Pediatr; 2021; 9():635152. PubMed ID: 34490152
[No Abstract] [Full Text] [Related]
9. A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials.
Janeway KA; Gros L; Schwartz S; Daugherty C; Gallardo E; Hill C; Thomas E; Ward S; Rizzari C
Pediatr Blood Cancer; 2023 Jun; ():e30506. PubMed ID: 37369988
[TBL] [Abstract][Full Text] [Related]
10. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
Taylor ZL; Mizuno T; Punt NC; Baskaran B; Navarro Sainz A; Shuman W; Felicelli N; Vinks AA; Heldrup J; Ramsey LB
Clin Pharmacol Ther; 2020 Sep; 108(3):635-643. PubMed ID: 32558929
[TBL] [Abstract][Full Text] [Related]
11. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.
Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A
Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862
[TBL] [Abstract][Full Text] [Related]
12. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature.
Boelens AD; Mathôt RAA; Vlaar APJ; Bouman CSC
Neth J Med; 2018 Jan; 76(1):36-39. PubMed ID: 29380731
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma.
Truong HL; Barreto JN; Mara KC; Hampel PJ; Micallef IN; Nowakowski GS; Thanarajasingam G; Thompson CA; Wang Y; Witzig TE; Herrmann SM; Leung N
JCO Oncol Pract; 2024 Feb; ():OP2300628. PubMed ID: 38408299
[TBL] [Abstract][Full Text] [Related]
14. Carboxypeptidase G2 rescue after high-dose methotrexate.
DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
[TBL] [Abstract][Full Text] [Related]
15. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
[TBL] [Abstract][Full Text] [Related]
17. Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis.
Kala J; Nelson R; Drudge C; Zhou A; Ward S; Bourque M
Clinicoecon Outcomes Res; 2023; 15():165-179. PubMed ID: 36919083
[TBL] [Abstract][Full Text] [Related]
18. A Dose-Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers.
Fukaya Y; Kimura T; Yoshimura K; Umemura K; Kawamoto H
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):364-371. PubMed ID: 34435467
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications.
Mulder MB; Huisman R; Engels FK; van der Sluis IM; Koch BCP
Ther Drug Monit; 2018 Aug; 40(4):383-385. PubMed ID: 29994985
[TBL] [Abstract][Full Text] [Related]
20. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury.
Sakran R; Milo G; Jabareen A; Artul T; Haim N; Litvak M; Ringelstein-Harlev S; Horowitz N; Efrati E; Assady S; Kurnik D
J Oncol Pharm Pract; 2022 Mar; 28(2):508-515. PubMed ID: 34668443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
